06 Aug 2021
Posted in Medical Devices
Over 921 million hepatitis tests expected by 2030, says GlobalData
Worldwide over 600 million IVD tests for Hepatitis B and Hepatitis C screening are sold each year and this annual figure is expected to reach 921 million by 2030, according to GlobalData. The leading data and analytics company notes that the market is fuelled by an increasing number of tests performed on pregnant women, donors of human cells, tissues, and cellular and tissue-based products.
Aliyah Farouk, Senior Medical Devices Analyst at GlobalData, comments: “Although the number of diagnostic tests are expected to increase, the World Health Organization’s (WHO) efforts to eliminate viral hepatitis as a public health threat by 2030 is not feasible. The elimination target is even less likely in low-income and middle-income countries (LMIC) and diagnosis for marginalized communities such as prisoners remains low.”
In general, the sale of testing devices is impacted by changes in the number of pregnant women, sperm donations, whole blood donations, and source plasma donations. Currently, the demand for source plasma donations far outstrips the supply. Countries with prominent source plasma businesses or activities such as Germany, the Czech Republic, and Austria are likely to experience growth in their Hepatitis B and Hepatitis C tests market.
Farouk continues: “The COVID-19 pandemic also affected the hepatitis market due to the interruption of testing services. China and India experienced a greater impact due to their high hepatitis burden and asymptomatic cases, which made diagnosis and treatment challenging. GlobalData expects the market to recover by the end of 2021 to pre-pandemic levels where the compound annual growth rate (CAGR) was 4%.”
According to GlobalData’s pipeline products database, there are 47 active products for Hepatitis B testing and 97 active products for Hepatitis C testing. Companies such as DiaSorin and Mindray have the most products in the pipeline, but Roche, Siemens and Abbott are the leaders in the Hepatitis B and Hepatitis C markets.
Farouk concludes: “Not all individuals infected with hepatitis undergo testing, with many people being unaware of their condition. Companies may wish to set-up outreach programs and advertising campaigns, aimed at targeting high-risk patient subgroups, geographical areas, and/or communities.”